##plugins.themes.academic_pro.article.sidebar##

Download
pdf

##plugins.themes.academic_pro.article.main##

Abstract

Steroids are hormone mediators that are synthesized commercially by humans and are used extensively in medicine. The cortex of the adrenal glands produces them naturally. They're used to treat steroid-responsive illnesses and dermatoses, which are a group of maladies. Corticosteroids are a two-edged sword: when used correctly and for a short period, they can provide significant benefit with a low incidence of side effects; however, the wrong dose and/or duration, as well as unmindful withdrawal after prolonged administration, can have disastrous consequences. Corticosteroids are employed in a variety of medical fields. In this review, we will discuss in detail all the metabolic sequelae and neurological effects of steroid use. Moreover, we are also going to discuss the adverse events associated with prolonged steroid use.

Keywords

Steroids metabolic sequelae Corticosteroids

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Tawhed Fadhil Jaber. (2022). Biochemical investigation of steroids on metabolic sequelae and neurobiological effects. Texas Journal of Agriculture and Biological Sciences, 4, 1–9. Retrieved from https://zienjournals.com/index.php/tjabs/article/view/1489

References

  1. Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid Adverse Effects. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK531462/
  2. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments, and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2–13.
  3. Glyn JH. The discovery of cortisone: a personal memory. BMJ. 1998 Sep 19;317(7161):822.
  4. AlShareef S, Gokarakonda S, Marwaha R. Anabolic Steroid Use Disorder. StatPearls [Internet]. 2021 Dec 15 [cited 2022 Jan 24]; Available from: https://www.statpearls.com/articlelibrary/viewarticle/17498/
  5. Taves MD, Gomez-Sanchez CE, Soma KK. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am J Physiol Endocrinol Metab. 2011 Jul;301(1): E11–24.
  6. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014 May;24(5):383–98.
  7. Iyer R, Handelsman DJ. Androgens. Front Horm Res. 2016;47:82–100.
  8. Givens ML, Deuster P. Androgens and Androgen Derivatives: Science, Myths, and Theories: Explored From a Special Operations Perspective. J Spec Oper Med. 2015;15(3):98–104.
  9. Fink J, Schoenfeld BJ, Hackney AC, Matsumoto M, Maekawa T, Nakazato K, et al. Anabolic-androgenic steroids: procurement and administration practices of doping athletes. Phys Sportsmed. 2019 Feb;47(1):10–4.
  10. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009 Dec;104(12):1966–78.
  11. Bordin DM, Bettim BB, Perdona GC, de Campos EG, De Martinis BS. Understanding alterations in blood and biochemical parameters in athletes that use dietary supplements, steroids, and illicit drugs. Toxicology. 2017 Feb 1;376:75–82.
  12. Öcal R, Öcal N. Can hemogram parameters be an indicator for the systemic effects of inhaled corticosteroids in COPD patients? A comparative review of different corticosteroids and different inhaler techniques. Int J Med Rev Case Rep. 2019;(0):1.
  13. McKay LI, Cidlowski JA. Physiologic and Pharmacologic Effects of Corticosteroids. Holland-Frei Cancer Medicine 6th edition [Internet]. 2003 [cited 2022 Jan 25]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK13780/
  14. Pountain GD, Keogan MT, Hazleman BL, Brown DL. Effects of single-dose compared with three days’ prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets. J Clin Pathol. 1993 Dec;46(12):1089–92.
  15. Schwartzman RA, Cidlowski JA. Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol. 1994 Dec;105(4):347–54.
  16. Mulrow PJ, Forman BH. The tissue effects of mineralocorticoids. Am J Med. 1972 Nov;53(5):561–72.
  17. Winter DC, Schneider MF, O’Sullivan GC, Harvey BJ, Geibel JP. Rapid effects of aldosterone on sodium-hydrogen exchange in isolated colonic crypts. J Membr Biol. 1999 Jul 1;170(1):17–26.
  18. Salyer SA, Parks J, Barati MT, Lederer ED, Clark BJ, Klein JD, et al. Aldosterone regulates Na(+), K(+) ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochim Biophys Acta. 2013 Oct;1833(10):2143–52.
  19. Fuller PJ, Young MJ. Mechanisms of Mineralocorticoid Action. Hypertension. 2005 Dec 1;46(6):1227–35.
  20. Hunter RW, Ivy JR, Bailey MA. Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity. J Physiol. 2014 Apr 15;592(Pt 8):1731–44.
  21. Almukhtar SE, Abbas AA, Muhealdeen DN, Hughson MD. Acute kidney injury associated with androgenic steroids and nutritional supplements in bodybuilders†. Clinical Kidney Journal. 2015 Aug 1;8(4):415–9.
  22. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clinical chemistry. 2007;53(4):766–72.
  23. Daher EF, Júnior GBS, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, et al. Acute kidney injury due to anabolic steroid and vitamin supplement abuse: report of two cases and a literature review. International urology and nephrology. 2009;41(3):717–23.
  24. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. Journal of the American Society of Nephrology. 2010;21(1):163–72.
  25. Gutkowski K, Christ A, Hartleb M. Liver Injury Induced by High-Dose Methylprednisolone Therapy: A Case Report and Brief Review of the Literature. Hepat Mon. 2011 Aug 1;11(8):656–61.
  26. Shimizu H, Shimizu T, Takahashi D, Asano T, Arai R, Takakuwa Y, et al. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report. BMC Musculoskeletal Disorders. 2019 Feb 19;20(1):88.
  27. Coelho J, Ozenne V, Dray X, Chaput U, Marteau P. Case of Prednisolone-induced Hepatitis in a Patient with Ulcerative Colitis. Inflammatory Bowel Diseases. 2013 Mar 1;19(3): E34–5.
  28. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 2013 Aug 15;9(1):30.
  29. Thau L, Gandhi J, Sharma S. Physiology, Cortisol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538239/
  30. Da Silva J a. P, Jacobs JWG, Kirwan JR, Boers M, Saag KG, Inês LBS, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285–93.
  31. McMahon M, Gerich J, Rizza P. Effects of glucocorticoids on carbohydrate metabolism. Diabetes/metabolism reviews. 1988;4(1):17–30.
  32. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Molecular and cellular endocrinology. 2007;275(1–2):43–61.
  33. Bauerle KT, Harris C. Glucocorticoids and Diabetes. Mo Med. 2016;113(5):378–83.
  34. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008 May;197(2):189–204.
  35. Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al. Harrison’s Principles of Internal Medicine, 17th Edition. 17th edition. New York: McGraw-Hill Professional; 2008. 2958 p.
  36. Ortega E, Rodriguez C, Strand LJ, Segre E. Effects of cloprednol and other corticosteroids on hypothalamic-pituitary-adrenal axis function. J Int Med Res. 1976;4(5):326–37.
  37. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006 Jun 15;55(3):420–6.
  38. Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF, et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011 Nov;70(11):1887–94.
  39. Sapolsky RM, Romero LM, Munck AU. How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions*. Endocrine Reviews. 2000 Feb 1;21(1):55–89.
  40. Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci. 2009 Oct;1179:19–40.
  41. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361–7.
  42. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988 Oct 1;38(10):1631–1631.
  43. Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):17–21.
  44. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003 Jul 8;61(1):104–7.
  45. McGrath P, Rawson-Huff N. Corticosteroids during continuation therapy for acute lymphoblastic leukemia: the psycho-social impact. Issues Compr Pediatr Nurs. 2010;33(1):5–19.
  46. Mrakotsky CM, Silverman LB, Dahlberg SE, Ayman MCA, Sands SA, Queally JT, et al. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep;57(3):492–8.
  47. Achar S, Rostamian A, Narayan SM. Cardiac and Metabolic Effects of Anabolic-Androgenic Steroid Abuse on Lipids, Blood Pressure, Left Ventricular Dimensions, and Rhythm. Am J Cardiol. 2010 Sep 15;106(6):893–901?
  48. Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):72–5.
  49. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014 May 1;4(5):e004587.
  50. Bowyer S, Lamothe M, Hollister J. Steroid myopathy: Incidence and detection in a population with asthma. Journal of Allergy and Clinical Immunology. 1985 Aug;76(2):234–42.
  51. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. International Journal of Dermatology. 2010 Mar;49(3):239–48.
  52. Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness: Current Opinion in Critical Care. 2005 Aug;11(4):381–90.
  53. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017 Apr;17(4):233–47.
  54. Poetker DM, Reh DD. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids. Otolaryngologic Clinics of North America. 2010 Aug;43(4):753–68.
  55. Feroze KB, Khazaeni L. Steroid Induced Glaucoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK430903/
  56. Shah S, Desai C, Desai M, Dikshit R. Steroid-induced central serous retinopathy. Indian journal of pharmacology. 2011 Sep 1;43:607–8.